<DOC>
	<DOCNO>NCT02614404</DOCNO>
	<brief_summary>The purpose study determine efficacy safety imatinib treatment uncomplicated P. falciparum malaria .</brief_summary>
	<brief_title>Imatinib 's Effect Suppression Malaria Parasites Patients With Uncomplicated Plasmodium Falciparum Malaria</brief_title>
	<detailed_description>An exploratory study examine efficacy safety imatinib mesylate suppression parasitemia patient uncomplicated Plasmodium falciparum malaria . In vitro study P. falciparum parasitized erythrocyte demonstrate inhibitor protein tyrosine kinase SYK prevent malaria parasite egress infect red blood cell thereby eliminate parasitemia . Although potent syk kinase inhibitor currently approve human use , bcr-abl tyrosine kinase inhibitor ( imatinib mesylate ( GleevecÂ® ) ) also exhibit weak ( 15-fold ) inhibition syk tyrosine kinase , FDA-approved treatment number human malignancy include chronic myelogenous leukemia GIST . Because imatinib take daily many year without significant toxicity , use obtain preliminary indication whether inhibition erythrocyte syk kinase suppress parasitemia patient P. falciparum malaria . If anti-malaria activity observe imatinib , resource commit develop inexpensive , potent syk kinase inhibitor dedicate treatment malaria .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Dihydroartemisinin</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Gender : adult select trial ; note female subject woman childbearing age . Age : 1850 year . Target disease : Uncomplicated Plasmodium falciparum malaria symptom sign complicate malaria include continuous high fever 390C , psychiatric disorder , confusion , neurological symptom , symptom sign functional impairment organ lung , kidney cardiovascular system ; symptom sign liver damage kidney damage symptom sign another complicate infection pneumonia , dengue fever , bacterial infection . P. falciparum &gt; 25.000 / mm3 WBC &lt; 4000 &gt; 10.000 /mm3 RBC &lt; 3.5x106/mm3 Platelets &lt; 40.000 /mm3 Hemoglobin &lt; 10 g/dL ALT 200 % upper limit ( 56 units/L ) AST 200 % upper limit ( 40 units/L ) Blood creatine 75 % upper limit ( men : 1.2 mg/dL , woman 1 mgdL ) Serum total protein &lt; 6 g/L Glycemia &lt; 50 mg/dL &gt; 200 mg/dL Standard urine test Serious alteration Concomitant treatment Antimalarial Drugs Anticoagulant therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Plasmodium falciparum</keyword>
	<keyword>Uncomplicated malarial</keyword>
	<keyword>imatinib mesylate</keyword>
	<keyword>antimalarial</keyword>
</DOC>